Curis Lifesciences Ltd (NSE SME)

IPO Details

Key Performance Indicators (KPI)

Company Financial (In ₹Crore) 

About Company

The company operates both domestically and internationally, manufacturing products under loan license, contract basis, and for its own brand marketing.

Curis Lifesciences serves over 100 corporate clients through contract manufacturing and 2 clients under its own brand in Yemen and Kenya.

Its product portfolio includes:

• General pharmaceutical tablets and capsules
• Oral liquids
• External preparations
• Sterile ophthalmic ointments

The company’s state-of-the-art manufacturing facility in Sanand, Gujarat, follows strict quality control standards to ensure high safety and efficacy.

Curis Lifesciences continues to strengthen its presence through diverse pharmaceutical formulations and customized contract manufacturing solutions.

Strength

Experienced Promoters and Strong Management Team: Led by promoters with 13–15 years of pharmaceutical industry experience and medical backgrounds, the company benefits from strategic leadership and effective day-to-day management that drives steady growth and client satisfaction.

Diverse Product Portfolio: Curis Lifesciences offers a wide range of pharmaceutical products, including tablets, capsules, oral liquids, external preparations, and sterile ophthalmic ointments, supported by valid manufacturing licenses (G/25/2225 and G/28/1632).

Strategically Located, WHO-GMP Certified Facility: The company’s WHO-GMP accredited plant in Sanand, Gujarat, provides strong infrastructure, skilled labor access, and global regulatory registrations in Yemen, Kenya, the Philippines, and Nigeria, ensuring quality and international reach.

Weakness

Dependence on Single Manufacturing Facility: The company’s operations are concentrated in Sanand, Ahmedabad (Gujarat), making it vulnerable to regional risks such as policy changes, natural disasters, or disruptions, which may adversely affect business and financial performance.

Regulatory Compliance and Approval Risks: Operating in a highly regulated pharmaceutical industry, any delay or failure in obtaining or renewing required approvals or regulatory changes could impact the company’s operations, strategy, and profitability.

Loan Repayment and Compliance Risk: Past delays in loan installment payments may expose the company to penalties or reputational risk despite improved internal processes, potentially affecting financial stability and goodwill.